



2500 Seventh Avenue, Altoona, PA 16603 (814) 949-

DATE: 5 September 1986

TO: Director, Nuclear Materials Safety & Safeguards
NRC
Region I Material Licensing Section
631 Park Ave.
King of Prussia, PA 19406

'86 SEP 24 A9:57

FROM: Charles A. Sutton, M.D.
Radiation Protection Officer

U.S. POST
LIC. FEE MGMT. BRANCH

RE: NRC License No. 37-03387-02

Dear Sir:

Please amend our medical isotope license No. 37-03387-02 as follows:

1. Add David A. Lynch, M.D. as a user as listed on previous material license No. 47-10458-01 (See Attached)
2. Delete Dr. Webster from the license.
3. Add an optional method i.e. sleeve attenuation method by using "Calichek" or "Lineator" for determining linearity of the dose calibrator.
4. Add I-131 Therapy for Thyroid carcinoma and Hyperthyroidism for David Schatanoff, M.D. (form 313 m., sup. B. attached.)

Thank you.

Charles A. Sutton
Charles A. Sutton, M.D.
Radiation Protection Officer

Sister Anne Trzeciak
Sister Anne Trzeciak
Executive Director

Amendment fee - \$120 enclosed

Log	<i>Sep. 15</i>
Remitter	
Check No.	<i>006644</i>
Amount	<i>\$120</i>
Fee Category	<i>7C</i>
Type of Fee	<i>Amendment</i>
Date Check Rec'd.	<i>9/24/86</i>
Date Completed	<i>9/25/86</i>
By:	<i>S. Kuntz</i>

106170

ML10

8702040493 861031
REG1 LIC30
37-03387-02 PDR

"OFFICIAL RECORD COPY"

nsored by the Sisters of the Holy Family of Nazareth

SEP 18 1986

NAME & ADDRESS:

David Alan Lynch, M.D.
Route #1 - Box 41P5
Bridgeport, W. Va. 26330

635 VILLA PL.
MORGANTOWN, WV 26505

PHONE:

(304) 599-1465

PLACE & DATE OF BIRTH:

Clarksburg, W. Va., September 30, 1946

MARITAL STATUS:

Divorced

EDUCATION & DEGREES:

Carnegie Mellon University, B.D. - 1968
Mechanical Engineering with Honors

MILITARY TRAINING:

U.S. Army Weapons Command, Rock Island
Arsenal, Rock Island, Illinois 1970-1971
Honorable Discharge

ADDITIONAL EDUCATION:

West Virginia University - January 1971 to
August 1971

MEDICAL TRAINING/EXPERIENCE:

Medical School:

West Virginia University School of Medicine
August 1971 - June 1975 M.D. 1975

Internship and
Residency:

Temple University Hospital
Department of Radiology
Philadelphia, Pennsylvania
July 1975 - June 1978

FELLOWSHIP:
Pediatric Radiology

The Children's Hospital
Department Of Radiology
Denver, Colorado
July 1, 1978 - June 30, 1980

Staff Positions:

United Hospital Center, July 1980 - June 1984
P.O. Box 1680
Clarksburg, W. Va. 26301

KRON Medical Corporation July 1984 - July 1985
1829 E. Franklin Street
Chapel Hill, NC 27514

Self-Employed
July 1985 - Present

Experience in Nuclear Medicine, Ultrasound,
CT, Angiography, Some Interventional Procedures

CERTIFICATION:

Diagnostic Radiology By American Board of
Radiology, June 7, 1980
"B" reader for Black Lung NIOSH, March 11, 1981

SOCIETIES:

Radiological Society of North America
Harrison County Medical Society
West Virginia Medical Society
American Medical Association

PA. MD 018550 E exp. Dec 31, '86

WV 10551 issued 8/5/85 reg. 1317 exp. Jan 30, '87



UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D. C. 20555

FCMLB:DJF
030-03375

OCT 8 1980

United Hospital Center, Inc.
ATTN: Mr. D. Max Francis
Administrator
P.O. Box 2308
Clarksburg, VA 26301

Gentlemen:

Enclosed please find Amendment No. 12 to Material License No. 47-01458-01. Note that we have not authorized David A. Lynch, M.D., to use all the materials listed under Groups IV and V of 10 CFR Part 35.100. In order to approve Dr. Lynch to perform therapeutic procedures, he must return to us a completed, signed preceptor statement (Supplement B-Form NRC-313M) demonstrating that he has the required clinical training as specified in Sections 3.a and 3.b of Appendix A to Regulatory Guide 10.8. Specifically, he must have treated:

1. One additional case of polycythemia vera, leukemia, and/or bone metastases or a combination of those three conditions with soluble phosphorus-32.
2. Three cases of intracavitary procedures using colloidal phosphorus-32 or gold-198.

As soon as we are in receipt of the above information, we will be happy to grant Dr. Lynch approval to use materials listed under Groups IV and V.

Your ALARA plan submitted and signed by Robert M. Timmons, Director of Radiology Services, is accepted and approved.

Sincerely,

Michael A. Lamastra
Material Licensing Branch
Division of Fuel Cycle and
Material Safety

Enclosures:

1. Amendment No. 12 to Material License No. 47-01458-01
2. Appendix A
3. Form NRC-313M

This Copy Is For Your Files

MATERIALS LICENSE

Supplementary Sheet

License Number 47-01458-01

Docket or

Reference No. _____

Amendment No. 14

United Hospital Center, Inc.
Route 19 South
Clarksburg, West Virginia 26301

In accordance with letter dated June 5, 1981, License Number 47-01458-01
is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by,
or under the supervision of, the following individual(s) for the materials
and uses indicated:

David A. Lynch, M.D.

Groups I, II and III

Iodine 131 for treatment of hyperthyroidism and
cardiac dysfunction

Harry A. Bishop, M.D.

ALL

Cordel A. De La Pena, M.D.

Licensed material of the types, quantities, and
forms specified in Sections 35.31(a) of 10 CFR
35 and 31.11(a) of 10 CFR 31 for use in accordance
with the provisions of paragraphs (a) and (c) of
Section 35.31, 10 CFR 35 and paragraphs (a), (c),
and (d) of Section 31.11, 10 CFR 31.

NOV 17 1981

Date _____

For the U. S. Nuclear Regulatory Commission

Joseph DeMedio
Material Licensing Branch

by _____

Division of Fuel Cycle and
Material Safety
Washington, D. C. 20555

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

KEY TO COLUMN C

FULL NAME

David Schatanoff, M.D.

STREET ADDRESS

Mercy Hospital
2500 Seventh Avenue

CITY

Altoona

STATE

PA

ZIP CODE

16603

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		N/A -- Not Applicable, currently licensed for Group VI materials. (ABR certified - Therapy)
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	6	
	TREATMENT OF HYPERTHYROIDISM	16	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT	N/A	
	INTRACAVITARY TREATMENT	N/A	
I-125 or Ir-192	INTERSTITIAL TREATMENT	N/A	
Co-60 or Cs-137	TELETHERAPY TREATMENT	N/A	
Sr-90	TREATMENT OF EYE DISEASE	N/A	
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

1/84 thru 6/86 more than 100 hours

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
Jack D. Schocker, M.D.

b. NAME OF INSTITUTION
Mercy Hospital

c. MAILING ADDRESS
2500 Seventh Ave.

d. CITY
Altoona PA 16603

5. MATERIALS LICENSE NUMBER(S)
37-03387-02

6. PRECEPTOR'S SIGNATURE

Jack D Schocker

7. PRECEPTOR'S NAME (Please type or print)

Jack D. Schocker, M.D.

8. DATE

8/18/86

BETWEEN: William O. Miller, Chief
License Fee Management Branch
Office of Administration

John E. Glenn, Chief
Nuclear Materials Section B
Division of Engineering and
Technical Programs

00 00 3030
02120
6/90

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED

Applicant/Licensee: Mercy Hosp.

Application Dated: 9-5-86

Control No.: 106170

License No.: 37-03387-02

2. FEE ATTACHED

Amount: \$120

Check No.: 006644

3. COMMENTS

Signed SLJ

Date 9-22-86

B. LICENSE FEE MANAGEMENT BRANCH

1. Fee Category and Amount: 7C \$120

2. Correct Fee Paid. Application may be processed for:

Amendment

Renewal

License

Signed S. Kimberley

Date 9/25/86